
Emergence of Vaccine-derived Polioviruses, Democratic Republic of Congo, 2004–2011

Nicksy Gumede, Olivia Lentsoane, Cara C. Burns, Mark Pallansch, Esther de Gourville, Riziki Yogolelo, Jean Jacques Muyembe-Tamfum, Adrian Puren, Barry D. Schoub, and Marietjie Venter

Polioviruses isolated from 70 acute flaccid paralysis patients from the Democratic Republic of Congo (DRC) during 2004–2011 were characterized and found to be vaccine-derived type 2 polioviruses (VDPV2s). Partial genomic sequencing of the isolates revealed nucleotide sequence divergence of up to 3.5% in the viral protein 1 capsid region of the viral genome relative to the Sabin vaccine strain. Genetic analysis identified at least 7 circulating lineages localized to specific geographic regions. Multiple independent events of VDPV2 emergence occurred throughout DRC during this 7-year period. During 2010–2011, VDPV2 circulation in eastern DRC occurred in an area distinct from that of wild poliovirus circulation, whereas VDPV2 circulation in the southwestern part of DRC (in Kasai Occidental) occurred within the larger region of wild poliovirus circulation.

Indigenous wild-type poliovirus (WPV) remains endemic to 3 countries: Nigeria, Afghanistan, and Pakistan (1). Poliovirus (PV) circulation has been sustained in several African countries after importation from a PV-endemic country, resulting in reestablished virus transmission. Worldwide, the number of cases decreased by 50% from 2010 to 2011 (2). In developing countries, live attenuated oral PV vaccine (OPV) is still the vaccine of choice. However, the virus can revert to virulence during

Author affiliations: National Institute for Communicable Diseases, Johannesburg, South Africa (N. Gumede, O. Lentsoane, A. Puren, B.D. Schoub, M. Venter); University of Witwatersrand, Johannesburg (N. Gumede, B.D. Schoub); University of Pretoria, Pretoria, South Africa (M. Venter); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (C.C. Burns, M. Pallansch); World Health Organization, Geneva, Switzerland (E. de Gourville); and National Institute for Biomedical Research, Kinshasa/Gombe, Democratic Republic of Congo (R. Yogolelo, J.J. Muyembe-Tamfum)

DOI: <http://dx.doi.org/10.3201/eid1910.130028>

OPV replication in humans, resulting in person-to-person spread and circulation of vaccine-derived PVs in areas with low rates of vaccination coverage (3). Substantial sequence drift occurs in circulating VDPVs (>1% nt difference in types 1 and 3, >0.6% nt difference in type 2), indicating prolonged replication of the vaccine strain in human populations and consequent changes in phenotypic properties of neurovirulence and transmissibility (3,4). Poliomyelitis outbreaks associated with circulating VDPVs have been reported in several countries, including Egypt (1982–1993), Haiti (2000–2001), Dominican Republic (2000–2001), Philippines (2001), Madagascar (2002 and 2005), China (2004), Cambodia (2005–2006), Indonesia (2005), and Nigeria 2005–2010 (4–11). As a result of accumulating evidence about the emergence and spread of circulating VDPVs, there are plans to stop using OPV and synchronously implement more widespread use of inactivated polio vaccine (12–15). A better understanding of VDPV persistence and circulation is crucial for deciding when and how to stop vaccination with OPV after WPVs have been eradicated (16–18).

In early 2001, indigenous WPVs were eliminated from DRC, but starting in 2006 and continuing through 2011, WPV was imported into DRC from Angola several times. During 2010–2011 in DRC, 2 genetic clusters of the Southeast Asian PV1 genotype circulated; this genotype was imported twice from India to Angola and subsequently to DRC. Since December 2011, no cases of infection with WPV have been detected in DRC (19).

Monovalent OPV types 1 and 3 and bivalent OPV effectively induce immunity because of a lack of interference by the type 2 component (20). Reliance on monovalent OPV1, monovalent OPV3, and bivalent OPV in supplemental vaccination activities has contributed to the emergence of VDPV2. These alternative OPV formulations are

more effective than trivalent OPV at inducing higher levels of population immunity to WPV1 and WPV3 because there is no interference from the type 2 OPV strain. No type 2-specific immunity is induced. To maintain population immunity to type 2 PV, the World Health Organization (WHO) recommends 2 doses of trivalent OPV each year.

We describe the genetic characterization of circulating VDPV2 associated with outbreaks in DRC. During 2004–2011, the same time that extensive circulating VDPV transmission occurred in Nigeria, VDPV2 excretion was found for 70 children with acute flaccid paralysis (10,11). The close genetic relationships among many of the viruses provide evidence for circulation in several regions of DRC.

Materials and Methods

Viruses

National authorities in DRC submitted fecal specimens from patients with acute flaccid paralysis to the National Institute for Biomedical Research, Kinshasa, for PV isolation by standard methods recommended by WHO. To determine serotype of PV isolates and whether the virus was wild or related to vaccine strains (known as intratypic differentiation), isolates were forwarded to the National Institute for Communicable Diseases in South Africa for characterization by PCR, ELISA, and partial genomic sequencing (21). The original fecal specimens from which these isolates were obtained were also sent to the National Institute for Communicable Diseases for confirmation of virus isolation results by methods recommended by WHO (22).

Intratypic Differentiation

Through use of PCR (21–23) and ELISA, as recommended by WHO, PV isolates were determined to be Sabin-like or non-Sabin-like strains (23–26). All serotyped PVs or virus isolates that had shown cytopathic effect in L20B cells were tested by using a reverse transcription PCR (RT-PCR) kit supplied by the Centers for Disease Control and Prevention (Atlanta, GA, USA), which included separate reactions with primers for panenterovirus; panpoliovirus; PV serotypes 1, 2, and 3 (23,24); and multiplexed primers for Sabin type 1, 2, and 3 PVs (25). The amplicons were separated on 10% polyacrylamide gels and visualized after staining with ethidium bromide. Additionally, serotyped PV monotypes were analyzed by using an ELISA developed by the National Institute for Public Health and the Environment (Bilthoven, the Netherlands) and identified as Sabin-like or non-Sabin-like strains by using specific cross-adsorbed antiserum (21). From 2007 on, a real-time PCR was used for intratypic differentiation of untyped L20B isolates with a positive cytopathic effect. Another real-time PCR was used for retrospective VDPV

screening of Sabin strains reported during 2004–2006 and for prospective screening of untyped strains isolated from 2009 on (27,28).

Sequencing

RNA was extracted from 140 μ L of cell culture supernatant by using a QIAamp viral RNA extraction kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's recommendations. RT-PCR was performed in a single step, as described (29). Briefly, the extracted RNA (10 μ L) was added to 90 μ L of the amplification mixture containing 10 μ L standard 10 \times reaction buffer, 100 μ M of each dNTP (Roche Diagnostics GmbH, Mannheim, Germany), 10 mM dithiothreitol, 80 pmol of each primer (Q8 and Y7), 20 U of placental RNase inhibitor (Roche Diagnostics GmbH), 12.5 U of avian myeloblastosis virus reverse transcriptase (Roche Diagnostics GmbH), and 5U of Taq DNA polymerase (Roche Diagnostics GmbH). RT was conducted at 42°C for 60 min in a GeneAmp 9700 thermocycler (Applied Biosystems, Foster City, CA, USA) followed by denaturation at 95°C for 3 min. Amplification consisted of 30 cycles (95°C for 30 sec, 42°C for 30 sec, and 60°C for 2 min). The amplicons were visualized by ethidium bromide staining after electrophoresis on 1.5% agarose gels as described (26).

Before sequencing, the RT-PCR products were purified with the QIAquick PCR purification kit (QIAGEN). The complete viral protein (VP) 1 gene (nt 2480–3385) was sequenced as described (29,30) by cycle sequencing with the BigDye Terminator version 3.1 Cycle Sequencing Kit (31) (Applied Biosystems). The DNA sequence was determined by using the ABI 3100 Genetic Analyzer, version 3.1 (Applied Biosystems). Raw data files were imported into the Sequencher software package version 4.1.4 (http://avaxho.mc/software/software_type/scientific/others/sequencher_414.htm) for assembly and editing, and consensus sequence files were produced.

Sequence Analysis

According to WHO guidelines, Sabin viruses that differ from Sabin 2 by >5 nt in the VP1 coding region are classified as VDPVs (4). To determine VP1 genetic diversity, we compared all complete VP1 sequences of VDPV2 isolates from patients with acute flaccid paralysis and their contacts with the sequence of the Sabin type 2 OPV reference strain (GenBank accession no. AY184220). Evolutionary distances were computed by using the Kimura 2-parameter method (32) and the neighbor-joining method (33,34). Phylogenetic trees were constructed by using MEGA5 (35) with 500 bootstrap replicates. Bootstrap values >80 (out of 100) are indicated on the tree.

The alignments (nucleotide and translated amino acid sequences) were analyzed by using GeneDoc version

2.6001 (www.psc.edu/biomed/genedoc) and MEGAs 5 (35) to identify specific mutations and positive selection. Assignment of isolates to independent VDPV2 emergences and lineage groups was based on pairwise VP1 capsid region sequence differences within and between lineage groups. Complete capsid region sequence differences were used when there was uncertainty about relationships that had been based on the VP1 region; complete genome sequences were used to identify possible recombination junctions (data not shown).

Results

Circulating VDPVs

In total, just over 600 viral isolates obtained from DRC during 2004–2011 were tested by RT-PCR by using panenterovirus; panpoliovirus; serotype-specific; and Sabin type 1, 2, and 3 virus-specific primers. Isolates received before implementation of diagnostic real-time PCR were further tested by ELISA, and both techniques identified the isolates as Sabin-like PVs. All isolates were further screened by using real-time RT-PCR, as has been implemented in the Global Polio Laboratory Network, which included a screen for VDPVs (9). The genetic variability of virus isolates was further investigated by performing nucleotide sequence analysis of the VP1 capsid region of isolates that were identified as possible VDPVs by the VDPV screening assay. Partial genomic sequencing confirmed that for

70 cases, VP1 sequence was $\leq 99.3\%$ identical to that of the parental Sabin serotype 2 strain (i.e., ≥ 6 nt substitutions), and the isolates were classified as VDPVs. In all isolates, VP1 amino acid changes associated with the reversion to virulence (3) were identified at position 143.

During 2004–2011, VDPV2s were isolated from fecal specimens from patients with acute flaccid paralysis in several regions of DRC (online Technical Appendix, wwwnc.cdc.gov/EID/article/19/10/13-0028-Techapp1.pdf). The first case occurred in Maniema Province, in Kindu District, on October 13, 2004. For the other provinces, 40 cases occurred in Katanga, 12 in Maniema, 6 in Orientale, 5 in Kasai Occidental, 4 in Équateur, 2 in Bandundu, and 1 in Sud Kivu (Figures 1 and 2). During 2010–2011, a total of 193 cases of WPV1 were also reported in DRC; some of the geographic areas where VDPVs were found overlapped. During this time, ongoing reestablished transmission of WPV1 in the eastern part of the country occurred in northeastern Katanga, whereas VDPVs were found in central Katanga. In 2010, in Kasai Occidental, southwestern DRC, a different genetic cluster of WPV1 was introduced from Angola and the Republic of Congo. The extensive area of WPV1 circulation overlapped with the more restricted area of circulation of VDPVs in Kasai Occidental (19).

Phylogeny of the VP1 Region of the VDPVs

Emergence of VDPV2 was first detected in Maniema Province in October 2004. No other related viruses were




Figure 1. Geographic distribution of vaccine-derived poliovirus type 2 from patients from the Democratic Republic of Congo (DR Congo). Viruses are represented by circles colored by lineage. Viruses that are not assigned to a lineage are categorized as unclassified.




Figure 2. Yearly incidence of vaccine-derived poliovirus type 2, Democratic Republic of Congo, 2004–2011. The total number of cases associated with vaccine-derived poliovirus type 2 is graphed for each year according to date of onset of paralysis. Viruses that are not assigned to a lineage are categorized as unclassified. VDPVs, vaccine-derived PVs.

detected (Figure 3). Emergence of VDPV was next detected in Katanga in July 2005 (Figure 3). Four additional polio cases with onset during the same month were identified in Katanga, and 2 others followed in August. Viruses from the patients with polio onset in July and August were closely related to each other, forming lineage Ka1, which circulated in the district of Kinkondja in Katanga. Circulation of this lineage apparently stopped abruptly in 2005; no additional related viruses were detected in later years. The other 4 viruses isolated during 2005 and 2007 represented independent VDPV emergence events in 3 provinces (Bandundu, Sud-Kivu, and Orientale).

In 2008, two concurrent VDPV2 outbreaks (lineages Ka2 and Ka3) were detected in Katanga (Figure 3). Both outbreaks continued into 2009 in central Katanga. Also in 2008, two individual VDPV emergence events were detected in Maniema and Orientale.

In 2009, an outbreak in Kasai Occidental was detected and continued into 2010 (Ko1 lineage). In June 2010, an outbreak was detected in Maniema Province in several districts (Ma1 lineage); the last case occurred in October 2010. In addition, in 2009 and 2010, individual VDPVs representing independent emergence events were detected in Equateur, Maniema, Oriental, and Katanga Provinces.

In late 2011, several VDPVs were detected in Katanga; 4 independent events of VDPV emergence were observed, 2 of which formed lineages consisting of 5 or 6 VDPVs with 0.6%–1.2% nt difference from Sabin 2 (Ka4 and Ka5). During the 7-year period, the Katanga outbreaks accounted for 40 VDPVs, which is more than half of the total number of VDPVs detected in DRC.

Discussion

We isolated VDPVs from fecal specimens from 70 patients with acute flaccid paralysis in DRC during 2004–2011. Sequence analysis of the VP1 coding region of these viruses showed that 51 isolates represented 7 circulating lineages of circulating VDPVs, and 19 others represented independent emergence events. The detection of several distinct circulating VDPV lineages in DRC reinforces previous observations that circulating VDPVs can emerge independently in locations where immunity to PV is inadequate, such as northern Nigeria, (11,36) where 24 emergence events were observed (11,37). Favorable conditions for VDPV emergence existed throughout much of DRC.

More than half of the VDPVs identified were associated with cases from Katanga and were isolated during 2005, 2008, 2009, and 2011. WPV1 circulated in Katanga in 2010 and 2011 in districts other than those with circulating VDPV. Social mobilization efforts to increase vaccination acceptance are ongoing in Katanga because of a relatively high frequency of parents who refuse to have their children vaccinated, some for religious reasons (38).

The relative risks for paralysis from WPV1 and VDPV2 seem to be driven primarily by the particular serotype; the disease-to-infection ratio is higher for type 1 than for type 2. In a study of acute flaccid paralysis patients in Nigeria, clinical characteristics of cases associated with VDPV infection were similar to those associated with cases of WPV1 infection (11). Similar studies have not been performed for DRC.

Vaccination activities conducted in response to the outbreaks in 2008 and 2009 probably contributed to the




Figure 3. Viral protein phylogenetic relationships among vaccine-derived polioviruses isolated from patients with acute flaccid paralysis, Democratic Republic of Congo, 2004–2011. The tree was rooted to the Sabin type 2 poliovirus sequence. The year of onset of paralysis is indicated at the beginning of each virus name, followed by a 5-digit identifier and the province of the case-patient. The numbers of nucleotide differences from the Sabin 2 prototype viral protein 1 sequence are indicated, followed by the name of the lineage. Bootstrap values >80 are indicated on the tree. Scale bar indicates nucleotide substitutions per site.

disruption of VDPV and WPV transmission in 2010. In response to the VDPV2 outbreak, mass vaccination campaigns were performed in areas of Maniema, Kasai Occidental, and Katanga. Trivalent OPV was used in these campaigns. Monovalent OPV1 and bivalent OPV were used to control circulating WPV1. After circulation of lineages Ka1–Ka3 had stopped, circulating VDPV was again detected in Katanga in late 2011 (Ka4 and Ka5). As in 2008, simultaneous emergence of >1 VDPV lineage occurred in Katanga. Several VDPVs were detected in 2012 in Katanga; their characterization is ongoing (Qi Chen et al., unpub. data).

Events that occurred early in the circulating VDPV emergence pathway were observed for some lineages. OPV strains that differ from Sabin strains by 1–5 nt are being

routinely identified by the sensitive VDPV screening assay in use in Global Polio Laboratory Network laboratories, and these minimally drifted Sabin-related viruses can occasionally be linked to circulating VDPVs. Figure 3 includes several isolates that differ from the Sabin 2 prototype VP1 sequence by 6 nt. A Katanga isolate that differed from the Sabin strain by 3 nt was genetically linked to a Katanga VDPV (13224) that differed from the Sabin strain by 6 nt (data not shown).

Before use of the sensitive VDPV screening assay was implemented, events that occurred early in the circulating VDPV emergence pathway were not observed. In the circulating VDPV type 1 outbreak in Hispaniola, early events were missed because of delayed recognition of the outbreak. The study of early events in circulating VDPV emergence is

yielding valuable information for use in planning the endgame strategy for polio eradication. It now seems necessary to synchronize the phase-out of OPV to minimize the emergence of circulating VDPVs, particularly circulating VDPV2. Emergence of VDPVs from the Sabin OPV2 strain has been much more frequent than emergence of VDPVs from OPV1 and OPV3. Discontinuation of the type 2 component of OPV is being considered as a strategy for reducing the frequency of circulating VDPV2 emergence (12).

In this study, each DRC viral lineage was found to be restricted to a limited geographic region. This finding is consistent with the relative lack of long-range transportation networks across DRC and the low rate of routine vaccination coverage throughout DRC, which results in gaps in immunity to type 2 PV. Without an extensively developed highway system, individual geographic regions tend to be isolated and human population movement is restricted. With limited movement of people across long distances, virus transmission is restricted. The situation in DRC contrasts with that in northern Nigeria, where large-scale population movement occurs between the west and east across the northern states. Wild and circulating VDPV lineages spread widely throughout the northern states of Nigeria (11).

The circulating VDPVs detected in DRC had recovered the 2 most important biological properties of WPVs, namely the capacity to cause paralytic disease in humans and the capacity for continuous person-to-person transmission. The origin of circulating VDPV2 in DRC was probably the result of low population immunity to PV because of a combination of low vaccination coverage in some communities (39) and the prior elimination of the indigenous WPV of the same serotype (20). Because WPV2 has not circulated anywhere globally since 1999, immunity to PV type 2 is not being stimulated through virus circulation. Routine vaccination coverage is low in many regions of DRC; estimated OPV3 coverage was 73% (40). Additional factors that probably facilitated circulation of VDPVs in some communities were poor hygiene, inadequate sanitation, and tropical climate. Because similar conditions exist elsewhere, ongoing high-quality surveillance will be essential for eliminating polio in Africa. The need for vigilance was confirmed by the detection of circulating VDPV2 and circulating VDPV3 in Ethiopia (Gumede et al., unpub. data), circulating VDPV2 in Chad, and circulating VDPV2 in Somalia (20). The occurrence of WPV outbreaks in DRC emphasizes the need to maintain high vaccine coverage and acute flaccid paralysis surveillance to minimize the risk for emergence of VDPVs or circulation of imported WPVs.

Acknowledgments

We thank the staff from the National Institute for Communicable Diseases and the DRC National Polio Laboratory for isolating and sequencing some of the viruses described in this

study, members of the Expanded Programme on Immunization team from the DRC for their technical contribution, Jane Iber and Beth Henderson for assistance with graphics, and Steve Oberste for critically reviewing the manuscript.

This work was supported in part by a grant from the Poliomyelitis Research Fund and WHO.

The GenBank accession numbers for the sequence reported in this paper are JQ691358–JQ691413 and JX424824–JX4248936.

Dr Gumede is a medical scientist with a PhD degree in molecular virology. She is in charge of the WHO Regional Reference Polio Laboratory at the National Institute for Communicable Diseases, a division in the National Health Laboratory Services, in South Africa. Her research interests include disease epidemiology, clinical research, and PVs.

References

1. World Health Organization. Poliomyelitis. Fact sheet no. 114, October 2012 [cited 2012 Dec 20] <http://www.who.int/mediacentre/factsheets/fs114/en/>
2. World Health Organization. Progress towards global polio eradication—status of wild poliovirus circulation in Africa, 2011. *Wkly Epidemiol Rec.* 2012;87:109–15.
3. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. *Annu Rev Microbiol.* 2005;59:587–635. <http://dx.doi.org/10.1146/annurev.micro.58.030603.123625>
4. World Health Organization. Summary of discussions and recommendations. 16th Informal Consultation of The Global Polio Laboratory Network; 2010, Sep 22–23; Geneva. Global Laboratory Network Publication and Reports [cited 2012 Dec 20]. http://www.polioeradication.org/Portals/0/Document/Resources/GPLN_publications/GPLN_Meeting_recommendations_2010.pdf
5. Liang X, Zhang Y, Xu W, Wen N, Zuo S, Lee LA, et al. An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. *J Infect Dis.* 2006;194:545–51. Epub 2006 Jul 26. <http://dx.doi.org/10.1086/506359>
6. Tong YB, Zhang DY, Zou J, Zhang L, Yu H, Liu M. An epidemiological study on vaccine derived polio virus circle in Zhenfeng County of Guizhou Province [in Chinese]. *Zhonghua Yu Fang Yi Xue Za Zhi.* 2005;39:321–3.
7. Centers for Disease Control and Prevention. Global update on vaccine-derived polioviruses, January 2006–August 2007. *Wkly Epidemiol Rec.* 2007;82:337–43.
8. Estivariz CF, Watkins MA, Handoko D, Rusipah R, Deshpande J, Rana BJ, et al. A large vaccine-derived poliovirus outbreak on Madura Island—Indonesia, 2005. *J Infect Dis.* 2008;197:347–54. <http://dx.doi.org/10.1086/525049>
9. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, January 2008–June 2009. *MMWR Morb Mortal Wkly Rep.* 2009;58:1002–6.
10. Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, Corander J, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. *N Engl J Med.* 2010;362:2360–9. <http://dx.doi.org/10.1056/NEJMoa0910074>
11. Wassilak S, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. *J Infect Dis.* 2011;203:898–909. <http://dx.doi.org/10.1093/infdis/jiq140>

12. Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, Garib Z, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. *Science*. 2002;296:356–9. Epub 2002 Mar 14. <http://dx.doi.org/10.1126/science.1068284>
13. Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R, Randriamanalina B, Guillot S, Balanant J, et al. Recombinant vaccine-derived polioviruses in Madagascar. *Emerg Infect Dis*. 2003;9:885–7. <http://dx.doi.org/10.3201/eid0907.020692>
14. Yang CF, Naguib T, Yang SJ, Nasr E, Jorba J, Ahmed N, et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. *J Virol*. 2003;77:8366–77. <http://dx.doi.org/10.1128/JVI.77.15.8366-8377.2003>
15. Jarzabek Z. End phase challenges of poliomyelitis eradication programme realization [in Polish]. *Przegl Epidemiol*. 2005;59:59–68.
16. Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis. “Endgame” issues for the global polio eradication initiative. *Clin Infect Dis*. 2002;34:72–7. Epub 2001 Nov 19. <http://dx.doi.org/10.1086/338262>
17. Wood DJ, Sutter RW, Dowdle WR. Stopping poliovirus vaccination after eradication: issues and challenges. *Bull World Health Organ*. 2000;78:347–57.
18. Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. *Am J Epidemiol*. 1999;150:1001–21. <http://dx.doi.org/10.1093/oxfordjournals.aje.a009924>
19. Centers for Disease Control and Prevention. Progress toward global polio eradication—Africa, 2011. *MMWR Morb Mortal Wkly Rep*. 2012;61:190–4.
20. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, July 2009–March 2011. 2011;60:846–50. *MMWR Morb Mortal Wkly Rep*. 2011;60:846–50.
21. van der Avoort HG, Hull BP, Hovi T, Pallansch MA, Kew OM, Crainic R, et al. Comparative study of five methods for intratypic differentiation of polioviruses. *J Clin Microbiol*. 1995;33:2562–6.
22. World Health Organization. Supplement to the WHO Polio Laboratory Manual. An alternative test algorithm for poliovirus isolation and characterization. 2004;4(Suppl 1) [cited 2012 Dec 20]. http://www.who.int/immunization_monitoring/Supplement_polio_lab_manual.pdf
23. Kilpatrick DR, Nottay B, Yang CF, Yang SJ, Da Silva E, Penaranda S, et al. Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. *J Clin Microbiol*. 1998;36:352–7.
24. Kilpatrick DR, Nottay B, Yang CF, Yang SJ, Mulders MN, Holloway BP, et al. Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residue at positions of codon degeneracy. *J Clin Microbiol*. 1996;34:2990–6.
25. Yang CF, De L, Holloway BP, Pallansch MA, Kew OM. Detection and identification of vaccine-related polioviruses by the polymerase chain reaction. *Virus Res*. 1991;20:159–79. [http://dx.doi.org/10.1016/0168-1702\(91\)90107-7](http://dx.doi.org/10.1016/0168-1702(91)90107-7)
26. Chezzi C. Rapid diagnosis of poliovirus infection by PCR amplification. *J Clin Microbiol*. 1996;34:1722–5.
27. Kilpatrick DR, Yang CF, Ching K, Vincent A, Iber J, Campagnoli R, et al. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. *J Clin Microbiol*. 2009;47:1939–41. <http://dx.doi.org/10.1128/JCM.00702-09>
28. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, April 2011–June 2012. *MMWR Morb Mortal Wkly Rep*. 2012;61:741–6.
29. Kilpatrick DR, Iber JC, Chen Q, Ching K, Yang SJ, De L, et al. Poliovirus serotype-specific VP1 sequencing primers. *J Virol Methods*. 2011;174:128–30. Epub 2011 Apr 2. <http://dx.doi.org/10.1016/j.jviromet.2011.03.020>
30. Liu HM, Zheng DP, Zhang LB, Oberste MS, Pallansch MA, Kew OM. Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China. *J Virol*. 2000;74:11153–61. <http://dx.doi.org/10.1128/JVI.74.23.11153-11161.2000>
31. Applied Biosystems. BigDye® terminator v3.1 cycle sequencing kit [cited 2012 Dec 20]. http://www.ibt.lt/sc/files/BDTv3.1_Protocol_04337035.pdf
32. Kimura Y, Yoshii S, Maeno K, Matsumoto T. Growth of poliovirus in HeLa cells persistently infected with HVJ (Sendai virus). *Microbiol Immunol*. 1980;24:39–49.
33. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. *Mol Biol Evol*. 1987;4:406–25.
34. Gascuel O, Steel M. Neighbor-joining revealed. *Mol Biol Evol*. 2006;23:1997–2000. Epub 2006 Jul 28. <http://dx.doi.org/10.1093/molbev/msl072>
35. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol*. 2011;28:2731–9. Epub 2011 May 4. <http://dx.doi.org/10.1093/molbev/msr121>
36. Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizu H, Nathanson N, et al. Circulating vaccine-derived polioviruses: current state of knowledge. *Bull World Health Organ*. 2004;82:16–23.
37. Burns CC, Shaw J, Jorba J, Bukbuk D, Adu F, Gumedé N, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. *J Virol*. 2013;87:4907–22. Epub 2013 Feb 13. <http://dx.doi.org/10.1128/JVI.02954-12>
38. United Nations Children’s Fund. Polio communications quarterly update. Report to the Independent Monitoring Board June 2011 [cited 2012 Dec 20]. http://www.unicef.org/media/files/IMB_Report_FINAL.pdf
39. Yan D, Li L, Zhu S, Zhang Y, An J, Wang D, et al. Emergence and localized circulation of a vaccine-derived poliovirus in an isolated mountain community in Guangxi, China. *J Clin Microbiol*. 2010;48:3274–80. Epub 2010 Jul 14. <http://dx.doi.org/10.1128/JCM.00712-10>
40. Centers for Disease Control and Prevention. Progress toward interrupting wild poliovirus circulation in countries with reestablished transmission—Africa, 2009–2010. *MMWR Morb Mortal Wkly Rep*. 2011;60:306–11.

Address for correspondence: Nicky Gumedé, National Institute for Communicable Diseases, a Division of the National Health Laboratory Services, No.1 Modderfontein Rd, Sandringham, Johannesburg, 2131, South Africa; email: nicksyg@nicd.ac.za

**EMERGING
INFECTIOUS DISEASES**

Free Online RSS Feed

in PubMed Central

Ahead of print

CME Peer-Reviewed

podcasts

GovDelivery



Emergence of Vaccine-Derived Polioviruses, Democratic Republic of Congo, 2004–2011

Technical Appendix

Technical Appendix Table. Vaccine-derived polioviruses isolated in the Democratic Republic of Congo, 2004– 2011

Isolate	Province	District	Date of onset	GenBank accession no.	Lineage
1793	Kat	Kinkondja	7/25/2005	JQ691358	Ka1
13192	Man	Kindu	10/13/2004	JQ691357	-
13193	Bdd	Inongo	1/1/2005	JQ691360	-
13194	Kat	Malemba-Nkulu	1/1/2005	JQ691361	Ka1
13195	Kat	Kinkondja	7/8/2005	JQ691362	Ka1
13196	Kat	Kinkondja	7/20/2005	JQ691363	Ka1
13197	Kat	Kinkondja	7/28/2005	JQ691364	Ka1
13198	Kat	Kinkondja	8/23/2005	JQ691365	Ka1
13199	Kat	Kinkondja	8/31/2005	JQ691366	Ka1
13200	Bdd	Inongo	9/9/2005	JQ691367	-
13201	Skv	Uvira	3/16/2007	JQ691368	-
13202	Ort	Bafwasende	12/15/2007	JQ691369	-
13203	Ort	Yaleko	1/19/2008	JQ691370	-
13204	Kat	Kinkondja	1/19/2008	JQ691371	Ka2
13205	Kat	Kinkondja	2/11/2008	JQ691372	Ka2
13206	Kat	Kinkondja	3/22/2008	JQ691373	Ka2
13207	Kat	Kinkondja	3/27/2008	JQ691374	Ka2
13208	Kat	Butumba	6/12/2008	JQ691375	Ka2
13209	Kat	Kinkondja	6/17/2008	JQ691376	Ka2
13210	Kat	Butumba	5/15/2008	JQ691377	Ka2
13211	Kat	Bukama	4/12/2008	JQ691378	Ka2
13212	Kat	Mukanga	6/12/2008	JQ691379	Ka2
13213	Man	Kindu	6/7/2008	JQ691380	-
13214	Kat	Mukanga	7/6/2008	JQ691381	Ka2
13215	Kat	Malemba-Nkulu	7/9/2008	JQ691382	Ka2
13216	Kat	Mulongo	7/29/2008	JQ691383	Ka3
13217	Kat	Malemba-Nkulu	8/29/2008	JQ691384	Ka2
13218	Kat	Malemba-Nkulu	9/25/2008	JQ691385	Ka3
13219	Kat	Mulongo	10/8/2008	JQ691386	Ka3
13220	Kat	Kinkondja	10/19/2008	JQ691387	Ka2
13221	Kat	Manono	12/15/2008	JQ691388	Ka3
13222	Kat	Manono	2/25/2009	JQ691389	Ka3
13223	Kat	Butumba	3/2/2009	JQ691390	Ka2
13224	Kat	Kabondo-Dianda	6/26/2009	JQ691391	-
13225	Koc	Kamuesha	8/9/2009	JQ691392	Ko1
13226	Ort	Banalia	12/15/2009	JQ691393	-
13227	Koc	Luebo	12/27/2009	JQ691394	Ko1
13228	Eqt	Yambuku	12/31/2009	JQ691395	-
13229	Koc	Kalonda - Ouest	2/24/2010	JQ691396	Ko1
13230	Man	Salamabila	3/3/2010	JQ691397	-
13231	Ort	Aketi	3/21/2010	JQ691398	-

Isolate	Province	District	Date of onset	GenBank accession no.	Lineage
13232	Man	Kibombo	4/20/2010	JQ691399	Ma1
13233	Koc	Kamuesha	4/22/2010	JQ691400	Ko1
13234	Eqt	Monieka	5/2/2010	JQ691401	-
13235	Man	Kindu	6/19/2010	JQ691402	Ma1
13236	Ort	Banalia	6/25/2010	JQ691403	-
13237	Man	Kindu	6/30/2010	JQ691404	Ma1
13238	Man	Samba	7/6/2010	JQ691405	Ma1
13239	Man	Alunguli	8/7/2010	JQ691406	Ma1
13240	Man	Kindu	8/13/2010	JQ691407	Ma1
13241	Man	Kailo	8/17/2010	JQ691408	Ma1
13242	Man	Kindu	8/22/2010	JQ691409	Ma1
13243	Eqt	Bumba	8/29/2010	JQ691410	-
13244	Eqt	Bumba	9/6/2010	JQ691411	-
13245	Koc	Tshikapa	9/24/2010	JQ691412	Ko1
13246	Man	Kampene	10/13/2010	JQ691413	Ma1
13247	Ort	Yahuma	3/1/2010	JQ691359	-
17294	Kat	Mukanga	10/17/11	JX424836	Ka5
17295	Kat	Mukanga	10/21/11	JX424835	Ka5
17296	Kat	Mukanga	11/5/11	JX424834	Ka5
17297	Kat	Mukanga	11/10/11	JX424833	Ka5
17298	Kat	Kinkondja	11/26/11	JX424832	-
17299	Kat	Kinkondja	11/10/11	JX424831	Ka4
17300	Kat	Butumba	12/20/11	JX424830	-
17301	Kat	Butumba	12/3/11	JX424827	Ka4
17302	Kat	Butumba	12/17/11	JX424829	Ka5
17303	Kat	Kinkondja	12/15/11	JX424826	Ka4
17304	Kat	Kinkondja	11/4/11	JX424825	Ka4
17305	Kat	Kinkondja	12/29/11	JX424824	Ka4
17306	Kat	Malemba-Nkulu	12/30/11	JX424828	Ka4